Japan Tobacco Corporation Reports Strong Financial Growth in Q1 2024

JTI by 2FIRSTS, edited by Sophia
May.09.2024
Japan Tobacco Corporation Reports Strong Financial Growth in Q1 2024
Japan Tobacco Inc. (JT) reported significant financial growth in Q1 of 2024, with revenue up 11.3% and net profit up 8.7%.

On May 9, Japan Tobacco Inc. (JT) released its financial report for the first quarter of 2024, showing significant financial growth for the company in that quarter. Operating income increased by 11.3% year-on-year to 740.3 billion yen (approximately 4.9 billion US dollars); net profit grew by 8.7% year-on-year to 157.3 billion yen (approximately 1 billion US dollars).

 

Japan Tobacco Corporation Reports Strong Financial Growth in Q1 2024
Financial report for the first quarter of 2024 | Source: JT

 

Data shows that compared to 2023, Japan Tobacco Inc.'s cigarette business revenue increased by 12.8%, or 6.6% at constant exchange rates, reaching 653.3 billion yen (approximately $43 billion). Adjusted net profit increased by 3%, or 4.9% at constant exchange rates, reaching 239.1 billion yen (approximately $1.5 billion); total cigarette sales volume decreased by 1.7% year-on-year, while sales of alternative tobacco products (such as heated tobacco products) increased by 25.2% year-on-year, with revenue increasing by 17.7%.

 

In certain markets, such as the UK, cigarette sales experienced a significant decline, dropping by 16.1%, according to the Japanese tobacco company. However, the overall market share of the tobacco market has increased in many markets, including Italy, the Philippines, Russia, and Taiwan, China.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24
Alan Zhao: What the Rise of Nicotine Pouches Means for Tobacco Retailers
Alan Zhao: What the Rise of Nicotine Pouches Means for Tobacco Retailers
Alan Zhao argues that nicotine pouches are no longer a niche alternative, but a force quietly reshaping the future of tobacco retail. For distributors and retailers, the real risk is not missing a trend—it is moving too late, after regulation tightens, shelf space hardens and the market begins to choose its winners.
Mar.31 by Alan Zhao | 2Firsts Perspectives
Morocco rolls out compulsory rules for e-cigarettes, muassel and nicotine pouches
Morocco rolls out compulsory rules for e-cigarettes, muassel and nicotine pouches
Starting February 2026, Morocco will apply its first mandatory standard governing “smoke-free” products—covering e-cigarettes, muassel and nicotine pouches. Drafted by IMANOR, the standard introduces detailed requirements on composition, labelling, traceability and safety, and will apply to imported products. Consumer advocates say clear labelling and traceability are essential, while urging stronger public-awareness efforts and resources.
Feb.03 by 2FIRSTS.ai
Illinois HB 4652 Targets Discarded Vapes, Would Require Manufacturer-Funded Disposal Programs
Illinois HB 4652 Targets Discarded Vapes, Would Require Manufacturer-Funded Disposal Programs
Illinois House Bill 4652 proposes e-cigarette companies establish and fund safe disposal programs to combat environmental risks.
Mar.09 by 2FIRSTS.ai
Alcohol, tobacco and cannabis use among Spanish students aged 14–18 hits historic lows
Alcohol, tobacco and cannabis use among Spanish students aged 14–18 hits historic lows
Spain’s 2025 Survey on Drug Use in Secondary Education (ESTUDES), presented by the Ministry of Health, reports historic lows in alcohol, tobacco and cannabis consumption among students aged 14 to 18. The survey shows past-30-day drinking fell from 56.6% in 2023 to 51% in 2025, tobacco use from 21.0% to 15.5%, and cannabis use from 15.5% to 11.6%.
Feb.09 by 2FIRSTS.ai
2Firsts Holds Second PMTA Compliance Training in Shenzhen, Highlighting U.S. Regulatory Framework and Corporate Compliance Capabilities
2Firsts Holds Second PMTA Compliance Training in Shenzhen, Highlighting U.S. Regulatory Framework and Corporate Compliance Capabilities
2Firsts held its second U.S. PMTA compliance training in Shenzhen, providing a systematic overview of the U.S. regulatory framework for e-cigarettes and corporate compliance strategies. Nearly 20 industry professionals from manufacturing, e-liquid and supply-chain companies attended. Participants who passed the exam received compliance certification. Registration for the third training session will open soon, alongside customized corporate training programs.
Mar.09